Aeterna Zentaris (NASDAQ:AEZS) Now Covered by StockNews.com

Posted by on Jun 15th, 2023

Equities researchers at StockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) in a research report issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $28.00 price objective on shares of Aeterna Zentaris in a report on Tuesday, March 28th.

Aeterna Zentaris Price Performance

Shares of AEZS opened at $2.84 on Thursday. The firm has a 50-day moving average of $2.89 and a 200-day moving average of $3.20. The company has a market cap of $13.80 million, a PE ratio of -0.57 and a beta of 1.35. Aeterna Zentaris has a one year low of $2.32 and a one year high of $8.63.

Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.88) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.19. The business had revenue of $2.13 million during the quarter, compared to the consensus estimate of $0.90 million. Analysts expect that Aeterna Zentaris will post -3.41 earnings per share for the current year.

About Aeterna Zentaris

(Get Rating)

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.

Featured Articles

Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.